UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

17 Patient-First, Patient-Focused: Our Purpose and Promise

Read More Share:

Feb

10 Partnering With the Dermatology Community to Improve Health Equity

Read More Share:

Feb

07 Benjamin Jessie and Kurt Hughes Use Combined 50+ Years in Industry to Create New Experiences and Forums for Colleagues

Read More Share:

Jan

30 Collaboration with Duke University Focuses on Health Equity for Adolescents in Uganda

Read More Share:

Jan

20 Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Read More Share:

Jan

18 Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Read More Share:

Jan

17 5 U.S. Organizations Receive Support from UCB Community Health Fund

Read More Share:

Jan

13 Patient-first: UCB is there to listen to patients, to not only learn more about them but also from them

Read More Share:

Jan

06 UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Read More Share:

Dec

23 UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Read More Share:

Categories

Archives

Feb

17

Patient-First, Patient-Focused: Our Purpose and Promise

Feb

10

Partnering With the Dermatology Community to Improve Health Equity

Feb

07

Benjamin Jessie and Kurt Hughes Use Combined 50+ Years in Industry to Create New Experiences and Forums for Colleagues

Jan

30

Collaboration with Duke University Focuses on Health Equity for Adolescents in Uganda

Jan

20

Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Jan

18

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Jan

17

5 U.S. Organizations Receive Support from UCB Community Health Fund

Jan

13

Patient-first: UCB is there to listen to patients, to not only learn more about them but also from them

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Choose Country

UCB in the U.S.

Patients

Innovation

Sustainability

Newsroom

Contact

Categories

Archives

Feb

17

Patient-First, Patient-Focused: Our Purpose and Promise

Feb

10

Partnering With the Dermatology Community to Improve Health Equity

Feb

07

Benjamin Jessie and Kurt Hughes Use Combined 50+ Years in Industry to Create New Experiences and Forums for Colleagues

Jan

30

Collaboration with Duke University Focuses on Health Equity for Adolescents in Uganda

Jan

20

Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Jan

18

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Jan

17

5 U.S. Organizations Receive Support from UCB Community Health Fund

Jan

13

Patient-first: UCB is there to listen to patients, to not only learn more about them but also from them

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Sustainability

Newsroom

Contact